New Oral VEGF-TKI, Tivozanib, Demonstrates Robust Anti-tumor Activity and Excellent Safety in Advanced Kidney Cancer Patients – Global Phase 3 TIVO-1 Trial Actively Recruiting
AVEO Pharmaceuticals has recently initiated enrollment in a Phase 3 clinical trial evaluating tivozanib– a new oral, once-daily, triple VEGF receptor inhibitor– in patients with advanced kidney cancer, with nearly 500 patients worldwide expected to participate. TIVO-1 is a randomized, controlled trial evaluating tivozanib compared to sorafenib (Nexavar®), an FDA and EMEA approved therapy for the treatment of advanced renal cell carcinoma (RCC). The primary endpoint of the trial is progression-free survival (PFS), while secondary endpoints include overall survival, objective response rate, duration of respon...
Source: Kidney Cancer Association - April 29, 2010 Category: Urology & Nephrology Source Type: news

Renal Cell (Kidney) Cancer Forum & Blog
Ask Dr. Anthony Ciarallo a Question Regarding Adult Renal Cell (Kidney) Cancer [forum section] 04/24/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 24, 2010 Category: Urology & Nephrology Source Type: news

EAU Congress in Barcelona tops attendance registrations
The congress will also tackle some of the most controversial issues in urology and the EAU's Scientific Committee has prepared a programme that covers a long list of urological topics ranging from paediatrics, bladder cancer, female urology, renal cell carcinoma, reconstruction and functional urology, benign prostatic obstruction, stones and minimal invasive therapy, to name a few. The Kidney Cancer Association is represented at this meeting through the participation of its board member and past chairman, Paula E. Bowen.04/13/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 13, 2010 Category: Cancer & Oncology Source Type: news

The Do's & Don'ts of Managing Your Kidney Cancer Treatment
Ask Dr. DeSilva Internet radio program: Sarah Wise Miller, chairman of the Board of Directors of the Kidney Cancer Association and a ten-year survivor of Renal Cell Carcinoma joins the show to discuss the do's and dont's of managing your Kidney cancer treatment. 04/07/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 4, 2010 Category: Urology & Nephrology Source Type: news

The Do's & Don'ts of Managing Your Kidney Cancer Treatment
Health Radio: Sarah Wise Miller, chairman of the Board of Directors of the Kidney Cancer Association and a ten-year survivor of Renal Cell Carcinoma joins host Dr. Derrick DeSilva to discuss the do's and dont's of managing your Kidney cancer treatment. 03/27/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 27, 2010 Category: Urology & Nephrology Source Type: news

Young Investigator Award Interim Progress Report
  "Predicting Response to Antiangiogenic Therapies in Renal Cell Carcinoma" The ASCO Cancer Foundation has recently communicated with our researchers on the progress they have made during the first six months of their grant term. We are excited to share with you the update we received from Dr. Stephen Keefe, currently at work at the Hospital of the University of Pennsylvania through the generous support of the Kidney Cancer Association. Here is what Dr. Keefe had to say about his research: “The grant is being used to provide salary support for the principal investigator, Dr. Stephen Keefe, for time s...
Source: Kidney Cancer Association - February 28, 2010 Category: Urology & Nephrology Source Type: news

Young Investigator Award Interim Progress Report
 "Predicting Response to Antiangiogenic Therapies in Renal Cell Carcinoma"The ASCO Cancer Foundation has recently communicated with our researchers on the progress they have made during the first six months of their grant term. We are excited to share with you the update we received from Dr. Stephen Keefe, currently at work at the Hospital of the University of Pennsylvania through the generous support of the Kidney Cancer Association. Here is what Dr. Keefe had to say about his research:“The grant is being used to provide salary support for the principal investigator, Dr. Stephen Keefe, for time spent ...
Source: Kidney Cancer Association - February 28, 2010 Category: Urology & Nephrology Source Type: news

How Kidney Cancer Research Benefits From The American Recovery and Reinvestment Act of 2009
  In this email to our CEO, Bill Bro, Shannon Bell, Director, Office of Advocacy Relations, at the National Cancer Institute, describes new initiatives in kidney cancer research.  Mr. Bro will attend the National Cancer Advisory Board meetings, in Bethesda, in his capacity as a liaison representing cancer survivors. Dear Bill:   I would like to take this opportunity to call your attention to several of NCI’s exciting initiatives funded through the American Recovery and Reinvestment Act of 2009 (ARRA) in both cancer research generally and in kidney cancer specifically. I am pleased to report t...
Source: Kidney Cancer Association - February 28, 2010 Category: Urology & Nephrology Source Type: news

How Kidney Cancer Research Benefits From The American Recovery and Reinvestment Act of 2009
 In this email to our CEO, Bill Bro, Shannon Bell, Director, Office of Advocacy Relations, at the National Cancer Institute, describes new initiatives in kidney cancer research.  Mr. Bro will attend the National Cancer Advisory Board meetings, in Bethesda, in his capacity as a liaison representing cancer survivors.Dear Bill: I would like to take this opportunity to call your attention to several of NCI’s exciting initiatives funded through the American Recovery and Reinvestment Act of 2009 (ARRA) in both cancer research generally and in kidney cancer specifically. I am pleased to report that ...
Source: Kidney Cancer Association - February 28, 2010 Category: Urology & Nephrology Source Type: news

Silencing of HIF-1 & #945; suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis
Hypoxia-inducible factor-1 & #945; (HIF-1 & #945;) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC). 02/14/2010 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 13, 2010 Category: Urology & Nephrology Source Type: news

Notes from the Eigth International Kidney Cancer Symposium
We are grateful to patient advocate Katherine Phillion for sharing her notes from our fall kidney cancer meeting.  Eigth International Kidney Cancer Symposium September 2009     Management of Small Renal Masses and Localized Renal Carcinoma Case Presentation and Background Robert G. Uzzo, M.D., FACS There are a lot of options available to manage small (
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news

Notes from the Eigth International Kidney Cancer Symposium
We are grateful to patient advocate Katherine Phillion for sharing her notes from our fall kidney cancer meeting. Eigth International Kidney Cancer SymposiumSeptember 2009  Management of Small Renal Masses and Localized Renal CarcinomaCase Presentation and BackgroundRobert G. Uzzo, M.D., FACSThere are a lot of options available to manage small (
Source: Kidney Cancer Association - January 25, 2010 Category: Urology & Nephrology Source Type: news

Patient Advocate's Notes From 8th International Kidney Cancer Symposium
  Eighth International Kidney Cancer Symposium September 2009     Management of Small Renal Masses and Localized Renal Carcinoma Case Presentation and Background Robert G. Uzzo, M.D., FACS There are a lot of options available to manage small (
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news

Patient Advocate's Notes From 8th International Kidney Cancer Symposium
 Eighth International Kidney Cancer SymposiumSeptember 2009  Management of Small Renal Masses and Localized Renal CarcinomaCase Presentation and BackgroundRobert G. Uzzo, M.D., FACSThere are a lot of options available to manage small (
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news

Risk of bilateral renal cell cancer
In a trial to ascertain the risk of developing bilateral kidney cancer, it was concluded that the risk of metachronous bilateral renal cell cancer (RCC) is drastically higher among pts first affected at a young age, suggesting a subset of early onset RCC with a strong genetic component.12/07/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 8, 2009 Category: Cancer & Oncology Source Type: news

Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago.  These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families.  The first installment sumarizes the Saturday morning session. Integration of Surgical and Systemic Therapy in Metastatic RCC  This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions.  T...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news

Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago.  These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families.  The first installment sumarizes the Saturday morning session.Integration of Surgical and Systemic Therapy in Metastatic RCC This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions.  The diversit...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news

NCCN Guidelines for Kidney Cancer Updated
to Include Pazopanib for Advanced Disease; Free Webinar Discusses Updates The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, PA — Following the recent FDA approval of pazopanib (Votrient™, GlaxoSmithKline) for advanced renal cell ca...
Source: Kidney Cancer Association - November 3, 2009 Category: Urology & Nephrology Source Type: news

NCCN Guidelines for Kidney Cancer Updated
to Include Pazopanib for Advanced Disease; Free Webinar Discusses UpdatesThe NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines.FORT WASHINGTON, PA— Following the recent FDA approval of pazopanib (Votrient™, GlaxoSmithKline) for advanced renal cell carci...
Source: Kidney Cancer Association - November 3, 2009 Category: Urology & Nephrology Source Type: news

NCCN Guidelines for Kidney Cancer Updated to Include Pazopanib for Advanced Disease; Free Webinar Discusses Updates
The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. November 3, 2009 FORT WASHINGTON, PA - Following the recent FDA approval of... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 3, 2009 Category: Cancer & Oncology Source Type: news

Renal Cell Cancer Survey
This survey will ask you questions about:   ·         Experiences you have had with RCC, and ·         Your preferences for possible medicines to treat RCC.     The survey will take about 25 minutes to complete and a $20 donation will be made to the Kidney Cancer Association to conduct further research on RCC treatments.   If you are interested in participating, please click on the link below:  https://oncology.rti.org/  08/04/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 4, 2009 Category: Urology & Nephrology Source Type: news

Renal Cell Cancer Survey
This survey will ask you questions about: ·        Experiences you have had with RCC, and·        Your preferences for possible medicines to treat RCC.  The survey will take about 25 minutes to complete and a $20 donation will be made to the Kidney Cancer Association to conduct further research on RCC treatments. If you are interested in participating, please click on the link below: https://oncology.rti.org/ 08/04/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 4, 2009 Category: Urology & Nephrology Source Type: news

Brownlee Fun Walk
July 10, 2009                                                                   FOR IMMEDIATE RELEASE CONTACT ELIZABETH HANSON-DELAGDO FOR MORE INFORMATION 262.595.3341       The Brownlee Fun Walk to be held on August 2 at UW-Parkside This new Family-Fun Walk will benefit the Kidney C...
Source: Kidney Cancer Association - July 17, 2009 Category: Urology & Nephrology Source Type: news

Brownlee Fun Walk
July 10, 2009                                                                  FOR IMMEDIATE RELEASECONTACT ELIZABETH HANSON-DELAGDOFOR MORE INFORMATION 262.595.3341   The Brownlee Fun Walk to be held on August 2 at UW-ParksideThis new Family-Fun Walk will benefit the Kidney Cancer As...
Source: Kidney Cancer Association - July 17, 2009 Category: Urology & Nephrology Source Type: news

Help refine questionnaire about treatment preferences for RCC
Would you be willing to help refine a questionnaire about treatment preferences for renal cell cancer?   If you are an adult and have taken medicine to treat your renal cell cancer in the past six months, you may qualify. This questionnaire asks questions about preferences for possible cancer medicines and side effects. David Cella (Northwestern University) would like to get your help to ensure it is a good questionnaire. The interview will take less than 30 minutes (over-the-phone), and you will be paid $50 if you are eligible and selected for the interview.   Dates: Thursday, June 11th - Tuesday, June 16th &nbs...
Source: Kidney Cancer Association - June 5, 2009 Category: Urology & Nephrology Source Type: news

Help refine questionnaire about treatment preferences for RCC
Would you be willing to help refine a questionnaire about treatment preferences for renal cell cancer? If you are an adult and have taken medicine to treat your renal cell cancer in the past six months, you may qualify. This questionnaire asks questions about preferences for possible cancer medicines and side effects. David Cella (Northwestern University) would like to get your help to ensure it is a good questionnaire. The interview will take less than 30 minutes (over-the-phone), and you will be paid $50 if you are eligible and selected for the interview. Dates: Thursday, June 11th - Tuesday, June 16th Hon...
Source: Kidney Cancer Association - June 5, 2009 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Announces Young Investigator Award
Stephen Keefe, M.D., of the University of Pennsylvania, is the receipient of the Kidney Cancer Association’s 2009 Young Investigator Award.  The announcement was made at an awards brunch on Sunday, May 31, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.  Dr. Keefe’s project is titled "Predicting Response to Antiangiogenic Therapies in Renal Cell Carcinoma." Bill Bro, Association CEO, and Carolyn Konosky, Development Director, attended the awards ceremony.  "We had an opportunity to speak with Dr. Keefe during brunch," Bro said.  "W...
Source: Kidney Cancer Association - June 1, 2009 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Announces Young Investigator Award
Stephen Keefe, M.D., of the University of Pennsylvania, is the receipient of the Kidney Cancer Association’s 2009 Young Investigator Award.  The announcement was made at an awards brunch on Sunday, May 31, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.  Dr. Keefe’s project is titled"Predicting Response to Antiangiogenic Therapies in Renal Cell Carcinoma."Bill Bro, Association CEO, and Carolyn Konosky, Development Director, attended the awards ceremony. "We had an opportunity to speak with Dr. Keefe during brunch," Bro said. "We we...
Source: Kidney Cancer Association - June 1, 2009 Category: Urology & Nephrology Source Type: news

"New advances deliver fresh hope in kidney cancer"
In her article, Malini Guha provides a concise and informative review of the current options and prospects of success in the treatment of renal cell carcinoma. The article comes across as both scientifically accurate and clearly comprehensible, aiming to give interested readers the necessary information on the latest research into treatment in this indication in a manner that is comprehensive and yet not overtaxing. Click here for the complete article (PDF).05/14/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 14, 2009 Category: Urology & Nephrology Source Type: news

NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus
NCCN has added everolimus (Afinitor®, Novartis) to the NCCN Guidelines for Kidney Cancer as a recommended treatment for patients with renal cell carcinoma whose disease has progressed after treatment with kinase inhibitors. This recommendation comes on the heels of the March 30, 2009 FDA approval of everolimus based upon results of a clinical trial which showed that the therapy significantly extended progression-free survival in a specific group of patients. April 20, 2009 FORT WASHINGTON,... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - April 20, 2009 Category: Cancer & Oncology Source Type: news

Simple Nomogram Risk-Stratifies Renal Cell Cancer Patients on Targeted Therapy
"This model can be used to stratify patients on clinical trials and in clinical practice," said Dr. Heng.03/05/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 6, 2009 Category: Cancer & Oncology Source Type: news

Targeted Therapy Improves Survival in Poor-Risk Renal Cancer
Patients with poor-risk renal cell carcinoma have improved survival with temsirolimus (Torisel) whether they have a nephrectomy or not.03/04/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2009 Category: Cancer & Oncology Source Type: news

Kidney Cancer Association Applauds UK Drug Approval
      Change of Tack Shows Policy Shift and Saves Lives Evanston, IL, February 5, 2009 – The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients.   “This decision demonstrates the power of a unified voice,” said W...
Source: Kidney Cancer Association - February 5, 2009 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Applauds UK Drug Approval
   Change of Tack Shows Policy Shift and Saves LivesEvanston, IL, February 5, 2009– The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients. “This decision demonstrates the power of a unified voice,” said William Br...
Source: Kidney Cancer Association - February 5, 2009 Category: Urology & Nephrology Source Type: news

NCCN Receives $4 Million Oncology Research Grant from Wyeth
NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding. January 15, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - January 15, 2009 Category: Cancer & Oncology Source Type: news

Earn $100 by participating in a survey by RTI-HS
Research Triangle Institute - Health Solutions (RTI-HS) is recruiting adults diagnosed with renal cell cancer to participate in a survey pretest. This survey will ask you questions about your experience with renal cell cancer and your preferences for possible cancer medicines. If you are 18 years of age or older and have been diagnosed with renal cell cancer; you may qualify. The interview will take an hour, and you will be paid $100 if you are eligible and selected for the interview. If you are interested in participating or have questions, please contact Lauren Weaver at 919-541-6594.  Click here for directions...
Source: Kidney Cancer Association - January 5, 2009 Category: Urology & Nephrology Source Type: news

Earn $100 by participating in a survey by RTI-HS
Research Triangle Institute - Health Solutions (RTI-HS) is recruiting adults diagnosed with renal cell cancer to participate in a survey pretest. This survey will ask you questions about your experience with renal cell cancer and your preferences for possible cancer medicines. If you are 18 years of age or older and have been diagnosed with renal cell cancer; you may qualify. The interview will take an hour, and you will be paid $100 if you are eligible and selected for the interview. If you are interested in participating or have questions, please contact Lauren Weaver at 919-541-6594.  Clickhere for directions ...
Source: Kidney Cancer Association - January 5, 2009 Category: Urology & Nephrology Source Type: news

In loving memory of Colleen Sigman
On August 6, 2007, Colleen Sigman passed away from renal cell carcinoma. Colleen Sigman is not just another statistic for kidney cancer she was a daughter, a wife, a mother, a grandma (maw maw), a niece, an Aunt, a sister-in-law, and a cousin and most of all she was my best friend and my life along with many others will never be the same without her. A few months before her death we found out that there were not many options out there for a patient with renal cell carcinoma. In this day and age you would think that we would be further along in all types of cancer than we really are today. We were shocked by the cost of me...
Source: Kidney Cancer Association - September 20, 2008 Category: Urology & Nephrology Source Type: news

In loving memory of Colleen Sigman
On August 6, 2007, Colleen Sigman passed away from renal cell carcinoma. Colleen Sigman is not just another statistic for kidney cancer she was a daughter, a wife, a mother, a grandma (maw maw), a niece, an Aunt, a sister-in-law, and a cousin and most of all she was my best friend and my life along with many others will never be the same without her. A few months before her death we found out that there were not many options out there for a patient with renal cell carcinoma. In this day and age you would think that we would be further along in all types of cancer than we really are today.We were shocked by the cost of medi...
Source: Kidney Cancer Association - September 20, 2008 Category: Urology & Nephrology Source Type: news

DOR BioPharma Forms orBec ® European Medical Advisory Board
Clinical trials are also underway testing allogeneic HSCT for treatment of some metastatic solid tumors such as breast cancer, renal cell carcinoma, melanoma and ovarian cancer. 09/19/2008 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 20, 2008 Category: Urology & Nephrology Source Type: news

Seeking patients with renal cell carcinoma for interviews
Dear Cancer Patient: We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who are currently taking or considering taking  a chemotherapy agent. These interviews are scheduled for Monday, September 29 and the morning of Tuesday, September 30   in our offices at: Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview  will last 60 minutes and the cash honorarium is $150 This is not sales. All information will be completely confidential.  Please ca...
Source: Kidney Cancer Association - September 11, 2008 Category: Urology & Nephrology Source Type: news

Seeking patients with renal cell carcinoma for interviews
Dear Cancer Patient:We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who arecurrently taking orconsidering taking a chemotherapy agent.These interviews are scheduled forMonday, September 29 and the morning ofTuesday, September 30  in our offices at:Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview will last 60 minutes and the cash honorarium is $150This is not sales. All information will be completely confidential. Please call me at312-604-40...
Source: Kidney Cancer Association - September 11, 2008 Category: Urology & Nephrology Source Type: news

Novartis Oncology launches a new mTOR Web site
The science of mTOR and its clinical implications are subjects of evolving understanding among the medical community. TargetmTOR.com will serve as a valuable resource to those who wish to learn more about the role of mTOR in cancer treatment. The site content includes a guide which explains how mTOR works in different diseases, including Renal Cell Carcinoma and Neuroendocrine Tumors. These are two types of cancer in which clinical trials are underway. The site features an animated, three-dimensional illustration depicting how mTOR works in cell metabolism, growth, proliferation, and angiogenesis. Site visitors can access ...
Source: Kidney Cancer Association - June 19, 2008 Category: Urology & Nephrology Source Type: news

Novartis Oncology launches a new mTOR Web site
The science of mTOR and its clinical implications are subjects of evolving understanding among the medical community. TargetmTOR.com will serve as a valuable resource to those who wish to learn more about the role of mTOR in cancer treatment. The site content includes a guide which explains how mTOR works in different diseases, including Renal Cell Carcinoma and Neuroendocrine Tumors. These are two types of cancer in which clinical trials are underway.The site features an animated, three-dimensional illustration depicting how mTOR works in cell metabolism, growth, proliferation, and angiogenesis. Site visitors can access d...
Source: Kidney Cancer Association - June 19, 2008 Category: Urology & Nephrology Source Type: news

Active Biotech to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
ANYARA - a novel cancer targeted therapy - is in Phase III trials with 500 advanced renal cell cancer patients. 05/15/2008 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 16, 2008 Category: Urology & Nephrology Source Type: news

Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients
HOLLYWOOD, Fla., March 13, 2008 — Several recently approved agents offer promising treatment possibilities for patients with metastatic renal cell carcinoma (RCC) and the order in which these agents are administered may positively impact clinical response, according to a presentation given during the National Comprehensive Cancer Network (NCCN) 13th Annual Conference: Clinical Practice GuidelinesandQuality Cancer Care. Until recently, there were very few agents to treat RCC and those available ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 13, 2008 Category: Cancer & Oncology Source Type: news

Novartis kidney cancer drug clears key hurdle
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy  Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus  Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR  Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008  Complete results to ...
Source: Kidney Cancer Association - February 28, 2008 Category: Urology & Nephrology Source Type: news

Novartis kidney cancer drug clears key hurdle
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR Results of RECORD-1 trial address unmet medical need in renal cell cancer withworldwide regulatory filings planned for second half of 2008 Complete results to be submitted as l...
Source: Kidney Cancer Association - February 28, 2008 Category: Urology & Nephrology Source Type: news

ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
ZymoGenetics has initiated Phase II testing of Interleukin 21 in combination with Nexavar tablets, in patients with advanced renal cell cancer. The primary objective of the open label multi-center Phase II study is to characterize safety of Interleukin 21 (IL-21) with Nexavar at the recommended dose; a secondary objective is to evaluate anti-tumor activity, which will be assessed by evaluating tumor response and progression free survival. The trial is expected to enroll approximately 30 patients. The study is evaluating the combination in patients with clear cell carcinoma, which accounts for 85% of all renal cell tumors. ...
Source: Kidney Cancer Association - January 16, 2008 Category: Urology & Nephrology Source Type: news